On March 29th, Songli Bio held a technical launch conference on the bio-soft tissue-inducing biomaterial platform in Shanghai Yuliu Chuangyuan. At the press conference, Songli Biotech released the clinical trial results of the “Surgical Bio-Sample†technology of the Loong Bio-soft tissue-inducing biomaterial platform technology product, and the latest patent for the new application “High-intensity Reproducible Artificial Ligamentâ€. Founded in 2002 and headquartered in Shanghai, Songli Biotech has successfully developed a fast-dissolving porcine blood fibrin adhesive with independent intellectual property rights. It can be widely used for surgical hemostasis and closed wounds. On September 20, 2017, Songli Bio completed the D round of financing, jointly led by Hualing Capital and Guijing Capital, Taifu Capital, Dynamic Balanced Capital and C-round Investor and the A-round investor Jiuzhou Ventures. cast. Traditional biomedical materials cannot meet the needs of clinical applications Biomedical materials are the products of mutual penetration and extension of materials technology, biotechnology and clinical medicine. Biorenewable materials are the frontier field of biomedical materials. With the strong support of China's industrial policies, they have broad development prospects and gradually develop into nationals. A booming sunrise industry in the economic structure. China Investment Advisory Network predicts that by 2018, the global medical device market will total sales of 440 billion US dollars, with a compound growth rate (2012-2018) of 4.5%. The rapid development of the medical device industry has brought huge impact to biomedical materials. Expansion capacity. In May 2015, the State Council issued "Made in China 2025", taking biomedicine and high-performance medical devices as the development direction of strategic industries, focusing on the development and breakthrough of new technologies such as high-value medical consumables such as fully degradable vascular stents and induced pluripotent stem cells. . Biomedical materials are classified into inert biomedical materials, active biomedical materials, and biomedical materials that are degradable and absorbable according to the biochemical reaction level of the materials in the physiological environment. At the press conference, He Hongbing, chairman of Songli Bio, said that the current biomedical materials are mainly classified into three types: conventional biomedical materials, allogeneic organs and tissues and allogeneic organs. For these three traditional biomedical materials, He Hongbing believes that these materials still cannot meet the needs of clinical applications. The first is the conventional biomedical materials. He Hongbing said that these materials are mainly inert and cannot be degraded in the body. They are unable to meet the needs of clinical applications in terms of performance and service life. Taking orthopedics as an example, Deng Lianfu, director of the Shanghai Institute of Trauma and Orthopaedics, said that it is possible to replace ligaments that have been damaged in the body in the field of orthopedics. However, Deng Lianfu said that after several generations of biomedical materials for ligament replacement, the nylon is still implanted in the body and the screws are fixed on the bone. From the performance point of view, under the action of this kind of material, the body and the material can only achieve the shape fit, the patient's postoperative life will still receive different degrees of influence; from the material life point of view, the material life will still be subject to the use time limit, etc. The impact of the aspect. This is followed by allogeneic bioscaffold materials, which are mainly derived from corpses. The amount of this material is extremely limited and may also lead to the spread of prion protein (the pathogen of mad cow disease). Finally, allogeneic bioscaffold materials are mainly derived from animal tissues. At present, bio-patches using the small intestinal submucosa (SIS) as a raw material have been widely used in clinical practice. The bio-slice is taken from the submucosal layer of the small intestine of the pig, and has achieved good therapeutic effects. However, the production process using such materials is complicated and requires decellularization. If the decellularization is not complete, resulting in residual cells and genetic material, the speed and quality of tissue regeneration will be seriously affected. This production process often takes several days or weeks, so the production cost is high, and patients are generally unable to bear the price of such products. Soft tissue inducing biomaterial Faced with the painful clinical application of traditional biomedical materials, He Hongbing believes that the current industrial technology and structure are undergoing revolutionary changes. The most prominent point is that traditional biomedical materials application thinking is mainly aimed at the recovery of morphology and mechanics. He believes that the future application of thinking for biomedical materials will develop towards healing, restoring function, and regenerating and reconstructing human organs. In this regard, Zhang Xingdong, an academician of the Chinese Academy of Engineering, took the lead in the international discovery and confirmed that inanimate biological materials can induce the regeneration of living organisms and organs, and form biological functions, establishing the original biomaterial osteoinduction theory, and further proposed " Tissue-induced biomaterials." Therefore, the research progress of hard tissue induction and regeneration in this theory has opened up a new direction in biomaterials and industrial development. He Hongbing said that Songli Bio was developed under the guidance of Academician Zhang Xingdong to develop soft tissue-inducing biomaterials, which are mainly made of biodegradable polymer materials and biomaterials. Nanofiber film material. For the electrospinning technology, Deng Lianfu explained that the material imitation of this technology is implanted into the body, and the material will gradually evolve into its own organs and tissues over time. Compared with the currently used soft tissue regeneration material acellular matrix (SIS) material, the advantages of the loose biological platform technology materials are reflected in three aspects: First of all, the technical material of the loose force biological platform itself does not contain cellular components, avoiding the risk of immune reaction caused by incomplete cell depletion and cell residue, and reducing the risk of corresponding long-term complications; Secondly, the electrospinning process is conducive to large-scale mass production, and the manufacturing cost is greatly reduced; Finally, product shape specifications are not limited by raw materials, which is beneficial to meet the different needs of clinical applications. This laid a solid foundation for the promotion and application of China's independent and innovative medical regenerative biomaterials at home and abroad. Referring to the commercial use of the technology, this conference will mainly illustrate the commercialization value of the two diseases of the Department of Sputum and Abdominal Surgery and Sports Medicine. From the perspective of hernia and abdominal wall surgery, Tang Jianxiong, deputy department head and professor of the Department of Surgery, Shanghai Hospital of Fudan University, said that although the current use of synthetic materials can be effective, the quality of postoperative quality of patients should be the focus of material evaluation. . Tang Jianxiong said that through the 33-month follow-up, from the two aspects of disease recurrence rate and pain degree, the experimental group using Songli Biological "surgical bio-patches" has an efficiency of 100%, compared with synthetic materials. There is no significant difference, but soft tissue-inducing biomaterials are safer in terms of the likelihood of infection after using the material. In the field of sports medicine, Zhao Jinzhong, director of the Sports Medicine Department of the Sixth People's Hospital of Shanghai, said that most of the domestic rotator cuff repairs are conservative, because the repair failure rate of this part is higher. For special parts such as the junction of muscle and tendon, traditional biomedical materials are even more difficult to repair and treat it as an incurable disease. By inducing reconstruction and regeneration of the joint capsule, it is expected to achieve tissue and organ repair in this field. In response to the commercialization of soft tissue-inducing biomaterials, He Hongbing also said that the technology will achieve a wide range of clinical applications in the future, such as cardiac surgery, urology, orthopedics, and thoracic surgery. Gelatin Size 00 Empty Capsule,Hard Empty Gelatin Capsules Size 00,Halal Certificated Vegetable Empty Capsules,Empty Separated Halal Gelatin Capsule Ningbo Jiangnan Capsule Co., Ltd. , https://www.ningbocapsule.com